The identification of late preterm infants as a high-risk group of infants has been an important public health breakthrough. These infants have suffered a relative 'silent morbidity and mortality' before the recognition that they have unique physiology and risks. These infants represent almost three-fourths of all premature births in the United States. Many of these infants, because of their birthweight and appearance, have been treated in Well Baby Nurseries and even discharged by 48 h of birth despite specific unidentified or unappreciated risks that have led to their readmission and possible severe morbidities or even death. Two common problems for these infants include neonatal hypoglycemia and severe hyperbilirubinemia. The definition of hypoglycemia remains controversial but is nonetheless a problem of increasing frequency in these infants.
Introduction
The recognition and description of late preterm infants as a high-risk group of patients has been an important public health breakthrough to prevent morbidity and mortality and hopefully, even lead to a decrease in rates of prematurity in the United States.
There are approximately 500 000 infants born preterm in the United States annually (births before 37 completed weeks of gestation) and these account for 12.5% of live births. Of these preterm births, greater than 70% (approximately 350 000 live births) are late preterm infants. That means they are between 34 0/7 and 36 6/7 weeks gestation. Most recently has come the additional recognition of the early term infant (37 0/7 to 38 6/7 weeks) as a unique group as well. These infants comprise 17.5% of live births or 700 000 that have additional risks vs term babies beyond 38 weeks gestation. 1 Therefore, both of these groups of infants have been identified as at risk for both short-and long-term consequences associated with either preterm or early term delivery. Figure 1 depicts these late preterm and early term definitions along a gestational time line from the first day of the last menstrual period through 41 6/7 weeks gestation.
The complications of prematurity and risks of these problems for late preterm infants vs term infants are listed in Table 1 . These include temperature instability, feeding difficulties, the need for mechanical ventilation and a number of problems related to metabolic immaturity. [2] [3] [4] [5] [6] Late preterm infants are 3.5 times more likely to suffer from two or more of these problems than are term infants. 6 It is not unusual for many of the late preterm infants to have to spend more than five hospital days in neonatal intensive care unit. 5 In addition, those 'larger' late preterm infants who are treated more like term infants and have a short stay after delivery are readmitted to the hospital at rates 1.5 to 3.0 times greater than term infants. 2, 7, 8 This has led to the description of these infants as the 'great impostors', as they look like and weigh similarly to term infants, but do not have the physiologic maturity of the term infant (personal communication, Lucky Jain).
In 2002, the neonatal mortality rate (deaths among infants 0 to 27 days chronologic age) for late preterm infants was 4.6 times higher than the rate for term infants (4.1 vs 0.9 per 1000 live births, respectively). This difference has actually widened when compared to 1995 data where there was a fourfold difference between late preterm and term infants (4.8 vs 1.2 per 1000 live births, respectively). This relationship also carries over into infant mortality. In 2002, the infant mortality rate for late preterm infants was also greater than the infant mortality rate for term infants (7.7 vs 2.5 per l000 live births, respectively). 6 As more attention has been paid to these late preterm infants as a group of preterm infants, we are learning more about their uniqueness. Among the most recent developments come revelations about developmental and the neurobiology of the growth and maturation of the brain during the final few weeks of gestation. Maturation of oligodendroglia, increasing neuronal arborization and connectivity, maturation of neurotransmitters and an increase in brain size of 30% occur in these previously unappreciated last 3 weeks of gestation. [9] [10] [11] In December 2007, the Committee on the Fetus and Newborn published a clinical report that defined late preterm and recommended a change in terminology from 'near-term' to late preterm. They also proposed guidelines for evaluation and management of these infants. 12 In Table 2 , I have adapted and modified the committee document of the salient features of the criteria for discharge of these infants.
The conference Evidence vs Experience and the articles included in this supplement review many of the cardiovascular and respiratory issues that are associated with late prematurity. The two unique problems of late preterms that I reviewed included management of jaundice and prevention of severe hyperbilirubinemia and the topic of neonatal glucose homeostasis.
Management of jaundice and prevention of severe hyperbilirubinemia in late preterm infants In July 2004, the Subcommittee on Hyperbilirubinemia of the American Academy of Pediatrics published a clinical practice guideline with recommendations for the management of hyperbilirubinemia in infants at 35 weeks of gestation or greater. 13 The approach is directed at reducing the frequency of severe neonatal hyperbilirubinemia (levels >17 mg per 100 ml) and bilirubin encephalopathy, whereas minimizing the risk of unintended harms such as increased parental anxiety, decreasing breastfeeding and hoping to avoid excessive cost or waste in our practices.
Hyperbilirubinemia is the most common clinical condition requiring evaluation and treatment in the newborn and the most common cause for hospital readmission during the first week of postnatal life. [14] [15] [16] [17] [18] Infants must be monitored for potential toxicity of bilirubin. We must have a plan in place to identify those who develop severe hyperbilirubinemia and the rare case that may proceed to acute bilirubin encephalopathy, evolving into kernicterus, a devastating, chronic and disabling condition characterized by the clinical tetrad of:
Choreoathetoid cerebral palsy High-frequency central neural hearing loss Palsy of vertical gaze Dental enamel hypoplasia, the result of bilirubin induced cell toxicity 19 There is an approximate eightfold increased risk of developing a total serum bilirubin greater than 20 mg per 100 ml in infants born at 36 weeks gestation (5.2%) vs those born at 41 or 42 weeks gestation (0.7 and 0.6%, respectively). 20 Approximately 1 in 650 to 1000 infants >35 weeks gestation develop total serum bilirubin values greater than or equal to 25 mg per 100 ml and 1 in 10 000 have levels greater than 30 mg per 100 ml. 17, 21 Although there are few population-based studies that provide data on the incidence of acute bilirubin encephalopathy or kernicterus, there is an overrepresentation of late preterm infants in the US Pilot Kernicterus Registry, a database of voluntarily reported cases of kernicterus. 22 An analysis of the 125 reported cases in the registry suggests that this condition should be largely preventable if health-care personnel follow the recommendations provided by the subcommittee guideline. 13 The key elements of these recommendations are listed in Table 3 .
These guidelines are based on hour-specific phototherapy ( Figure 2 ) and exchange transfusion (Figure 3 ) treatment thresholds for three separate groups of neonates 13 and these are as follows:
Infants at lower risk (at least 38 weeks gestation and well) Infants at medium risk (at least 38 weeks gestation with risk factors, defined as isoimmune hemolytic disease, G6PD deficiency, asphyxia, significant lethargy, temperature instability, acidosis or albumin less than 3.0 g per 100 ml or 35 0/7 to 37 6/7 weeks gestation and well) Infants at higher risk (35 0/7 to 37 6/7 weeks gestation with risk factors)
Postnatal glucose homeostasis in late preterm infants There is limited evidence and no consensus regarding the definition of neonatal hypoglycemia (NH), who is at risk, when screening should be performed, the level and duration of NH that may cause neurologic sequelae and the interaction with other conditions, such as HIE, that frequently occur simultaneously. 23 It is clear that no single concentration of plasma glucose is always associated with the appearance of clinical signs that might be attributed to NH or the direct causation of cerebral injury. 24 Treatment should be based, therefore, on a more flexible approach guided by clinical assessment and not solely on plasma glucose concentration. 25, 26 Despite many studies that indicate NH might be a significant problem, we are still left without certainty and/or consistency when analyzing the data in light of the methodologic limitations of the studies themselves. 24 To help resolve the clinical dilemmas that result, Cornblath et al. 27 suggested that clinical management of NH be based on four basic principles:
Monitoring infants at high risk Confirming that the plasma glucose concentration is low Demonstrating that the clinical manifestations were because of the low plasma glucose by showing that they resolve after restoring plasma glucose to normoglycemic levels Observing and carefully documenting all of these events The algorithm in Figure 4 attempts to use these Cornblath principles to provide a more consistent approach to diagnosis and (5) Interpret all bilirubin levels according to infant's age in hours (6) Perform a systematic assessment on all infants before hospital discharge (7) Provide parents with written and oral information about newborn jaundice (8) Provide appropriate follow-up based on postnatal age at discharge and the predischarge risk assessment. Clinical judgment should be used in determining the timing of follow-up. Earlier or more frequent follow-up should be provided for those who have risk factors for subsequent severe hyperbilirubinemia, whereas those discharged with few or no risk factors can be seen after longer intervals (9) When indicated, treat newborns with intensive phototherapy or other recognized therapeutic interventions, including exchange transfusion. Measurement of albumin and calculation of the bilirubin/albumin ratio is recommended in addition to but not in lieu of total bilirubin level as an additional factor in determining the need for an exchange transfusion treatment. Its aims are to alleviate acute symptoms and any physiologic or neurologic abnormalities related to significantly low plasma glucose concentrations while preventing permanent sequelae.
It is beyond the scope of this article to go into the justification for each of the decisions in the algorithm and it is presented only to stimulate thought and provide a template for practices or institutions to frame their own clinical guides. Infants at medium risk (≥38 wk+risk factors or 35-37 6/7 wk and well)
Infants at lower risk (≥38 wk and well) Figure 2 Phototherapy guideline from the 2004 practice parameter of the American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Use total bilirubin. Do not subtract direct-reacting or conjugated bilirubin. Risk factors include isoimmune hemolytic disease, G6PD deficiency, asphyxia, significant lethargy, temperature instability, sepsis, acidosis or albumin less than 3/0 g per 100 ml (if measured). For well infants (35 0/7 to 37 6/7 weeks), we can adjust total serum bilirubin (TSB) levels for intervention around the medium risk line. It is an option to intervene at lower TSB levels for infants closer to 35 weeks and at higher TSB levels for those closer to 37 6/7 weeks. 12 ) or if total serum bilirubin (TSB) is X5 mg per 100 ml (85 mmol l À1 above these lines). Risk factors include isoimmune hemolytic disease, G6PD deficiency, asphyxia, significant lethargy, temperature instability, sepsis and acidosis. Measure serum albumin and calculate B/A ratio (see Table 2 ). Use total bilirubin. Do not subtract direct-reacting or conjugated bilirubin. If infant is well and 35 0/7 to 37 6/7 weeks (medium risk), we can individualize TSB levels for exchange based on actual gestational age. 
Conclusion
The delivery of infants who are physiologically mature and capable of successful transition to the extrauterine environment is the priority of all health-care providers in perinatal medicine. However, we have noted over the last 15 years the percentage of infants born in the United States before 40 weeks gestation has increased dramatically and the majority of the increase comes from the late preterm infant cohort. There is the possibility of a significant price to be paid for even this 'modest' degree of prematurity. It comes in the form of acute complications as reviewed in this article and the emerging realities that there may be long-term adverse outcomes relating to brain development with birth before 37 completed weeks of gestation.
As we move forward, our challenges are to provide safer strategies to optimize the outcomes of these infants while simultaneously researching the causes for the increase in late preterm births and developing interventional strategies to either prevent them and/or improve their outcomes.
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